Comparison of the neurocognitive outcomes in term infants treated with levetiracetam and phenobarbital monotherapy for neonatal clinical seizures. (August 2020)

• Record Type: Journal Article
• Authors: Arican, Pinar; Olgac Dundar, Nihal; Mete Atasever, Neslihan; Akkaya Inal, Mine; Gencpinar, Pinar; Cavusoglu, Dilek; Akbay, Sinem; Tekgul, Hasan
• Is Part Of: Seizure. Volume 80(2020)
• Page Start: 71
• Page End: 74
• Publication Date: 2020-08
• Subjects: Infant -- Monotherapy -- Neonatal -- Neurodevelopment -- Seizure; Epilepsy -- Periodicals; Epilepsy -- Periodicals; Seizures -- Periodicals; Épilepsie -- Périodiques; Electronic journals; Electronic journals; 616.853
• DOI: 10.1016/j.seizure.2020.06.006
• Languages: English
• ISSNs: 1059-1311

Abstract

Highlights: There is a restricted data of the antiepileptic drugs on neurocognitive outcome measures for neonatal seizures. Phenobarbital and levetiracetam monotherapy were associated with similar neurodevelopmental outcome in neonatal seizures. Our findings suggest that levetiracetam may be an alternative therapeutic option for neonatal seizures. Abstract: Purpose: This study aims to compare the neurocognitive outcome in term infants who were treated using phenobarbital (PB) and levetiracetam (LEV) monotherapy for neonatal clinical seizures. Methods: Term infants who were treated using PB or LEV monotherapy as the first-line anti-epileptic treatment for neonatal clinical seizures and followed-up in a pediatric neurology outpatient clinic were enrolled in this study. Neurodevelopmental outcome assessments were carried out using the Bayley Scales of Infant Development, third edition (BSID-III), including cognitive, receptive language, expressive language, fine motor and gross motor subscales. Results: The study group consisted of 62 infants who received monotherapy with PB monotherapy (n = 22) and LEV (n = 40). The mean duration of monotherapy treatment was 8 ± 6 months. There was no statistically significant difference between PB and LEV monotherapy groups concerning each outcome parameter on the BSID-III. There was also no statistically significant difference between PB and LEV monotherapy subgroups excluding the infants with neurodevelopmental impairment with a BSID-III scale score<7 or a composite score<85. Conclusion: Our findings suggest that both LEV and PB therapy can be equally safe as monotherapy for neonatal clinical seizures for the neurodevelopmental outcome assessment with BSID-III.